Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Spark Therapeutics Inc    ONCE

SPARK THERAPEUTICS INC

(ONCE)
  Report  
SummaryNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Spark Therapeutics : Swiss drugmaker Roche ups outlook as sales growth offsets price hit

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/17/2019 | 04:53am EDT
FILE PHOTO: Logo of Swiss drugmaker Roche is seen at its headquarters in Basel

ZURICH (Reuters) - Swiss drugmaker Roche lifted its 2019 outlook on Wednesday, as sales growth in China and the United States outpaced price declines it has suffered amid President Donald Trump's pressure on the industry to hold down charges.

Roche, the world's biggest cancer drug maker, now sees mid single-digit revenue growth, up from the previous forecast of low- to mid-single digit growth. It sees core earnings per share mirroring sales growth.

Drugs division chief Bill Anderson said Roche's drug revenue is soaring even as it honors a price-freeze pledge it made last year after Trump took to the phone and Twitter to urge companies to back off price hikes.

"We haven't taken any price increases in the U.S. since July 1," Anderson said on a call. "Overall in the world, our 10 percent sales growth in pharma was based on 15 percent volume growth and 5 percent average price declines across the portfolio."

Chief Executive Severin Schwan is getting a lift as sales of newer drugs offset erosion of older cancer drugs that face fierce competition in Europe.

Multiple sclerosis drug Ocrevus's sales rose by two-thirds to 836 million francs, while cancer immunotherapy Tecentriq jumped two-fold to 336 million. Breast cancer medicine Perjeta rose 41 percent to 870 million francs and Hemlibra, Roche's new haemophilia A drug, hit 219 million francs.

"I'm very pleased that 90 percent, the vast majority of our growth, comes from our new medicines," Schwan said.

Still, a big unknown for the Austrian CEO is how swiftly rivals' soon-to-be-launched copies of Roche's $22 billion-per-year cancer medicines Rituxan, Herceptin and Avastin will eat into U.S. sales this year and next.

"Roche can keep up the unbroken growth, as long as Ocrevus, Hemlibra and the entire (breast cancer) franchise maintain their momentum," Zuercher Kantonalbank analyst Michael Nawrath said.

Schwan expects the $4.3 billion takeover of Philadelphia-based Spark Therapeutics to be completed by June, despite a regulatory hiccup with the U.S. Federal Trade Commission that required an extension.

"Our firm expectation is it will close at the conditions we have offered," the CEO said.

First-quarter sales rose 8 percent to 14.8 billion Swiss francs ($14.7 billion), beating the 14.2 billion Infront Data poll average estimate. Drug sales rose 10 percent to 11.9 billion francs, besting the 11.2 billion poll average, while diagnostics sales edged higher.

Roche shares were little changed at 269 francs by 0800 GMT, beating a 1.5 percent drop in the STOXX Europe 600 Health Care Index.

(Reporting by John Miller; Editing by Michael Shields and David Holmes)

By John Miller

Stocks mentioned in the article
ChangeLast1st jan.
ROCHE HOLDING LTD. -0.51% 264.8 Delayed Quote.9.35%
SPARK THERAPEUTICS INC End-of-day quote.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SPARK THERAPEUTICS INC
05/18ROCHE : suffers third delay on Spark deal
AQ
05/16ROCHE : extends offer period in $4.3bn Spark takeover
AQ
05/15SPARK THERAPEUTICS : Roche and Spark Therapeutics, Inc. announce expected refili..
AQ
05/14Roche Extends Offer Period for Spark Therapeutics
DJ
05/14SPARK THERAPEUTICS : Roche pushes back Spark takeover again as regulatory review..
RE
05/14ROCHE : and Spark Therapeutics, Inc. announce expected refiling date of Premerge..
AQ
05/10SPARK THERAPEUTICS : Management's Discussion and Analysis of Financial Condition..
AQ
04/29SPARK THERAPEUTICS : Roche and Spark Therapeutics, Inc. announce withdrawal and ..
AQ
04/26SPARK THERAPEUTICS : Roche faces further delay in $4.3 billion Spark deal amid F..
RE
04/17Spark Therapeutics Announces Sponsorship of Believe Limited's First-Ever Scie..
GL
More news
Financials ($)
Sales 2019 112 M
EBIT 2019 -199 M
Net income 2019 -190 M
Finance 2019 370 M
Yield 2019 -
P/E ratio 2019 -
P/E ratio 2020
EV / Sales 2019 33,7x
EV / Sales 2020 21,8x
Capitalization 4 135 M
Chart SPARK THERAPEUTICS INC
Duration : Period :
Spark Therapeutics Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 19
Average target price 107 $
Spread / Average Target -0,32%
EPS Revisions
Managers
NameTitle
Jeffrey D. Marrazzo Chief Executive Officer & Director
Katherine A. High President, Director & Head-Research & Development
Steven M. Altschuler Chairman
Stephen W. Webster CFO & Principal Accounting Officer
Federico Mingozzi Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
SPARK THERAPEUTICS INC4 135
GILEAD SCIENCES6.09%84 380
VERTEX PHARMACEUTICALS1.82%43 215
REGENERON PHARMACEUTICALS-18.36%32 850
GENMAB7.78%10 630
SAREPTA THERAPEUTICS INC11.49%9 022